New drug aims to halt Alzheimer's decline in Early-Stage patients
Disease control
Not yet recruiting
This study tests a drug called TML-6 in 210 people with early Alzheimer's disease. Over 52 weeks, researchers will compare those taking TML-6 to those on a placebo to see if the drug can slow or stop memory and thinking problems. The goal is to find a treatment that helps people …
Phase: PHASE2 • Sponsor: Merry Life Biomedical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC